Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase
Observational
Started
2021-01-01
Last updated
2024-12-12
Condition(s) studied
Squamous Cell Lung Cancer
Investigational drug(s) / intervention(s)
Efficacy observation
Efficacy observation: Observation about the efficacy of sq-NSCLC patients receiving immunotherapy combined with or without chemotherapy as first-line treatment.
Study summary
The aim of this observational study is to investigate the treatment trajectory of immunotherapy in patients with squamous non-small cell lung cancer (sq-NSCLC). The primary objective is to identify potential indicators that can predict the efficacy of immunotherapy and explore strategies to prolong its effectiveness in sq-NSCLC patients. Biological specimens and medical imaging data will be collected from patients already receiving immunotherapy as a first-line treatment, and follow-up will be conducted to analyze prognosis based on different patterns.
Eligibility
Sex
ALL
Min age
18 Years
Max age
80 Years
Healthy volunteers
No
Inclusion Criteria:
* Diagnosed with sq-NSCLC;
* Receiving immunotherapy combined with or without chemotherapy as first-line treatment;
* ≥ 18 years and ≤ 80 years old;
* No previous treatment in the lungs or any other organ.
Exclusion Criteria:
* History of cancer treatment;
* History of other malignant tumors;
* Irregular treatment or poor compliance;
* Incomplete clinical information or lost to follow-up.
Primary outcome measure(s)
progression-free survival — A two-year period after starting treatment (Regular follow-up every three months after receiving immunotherapy combined with or without chemotherapy as first-line treatment) The time of disease progression is evaluated according to the Response Evaluation Criteria in Solid Tumors, version 1.1.
Trial sites (1)
Facility
City
Region
Status
Union Hospital, Tongji Medical college, Huazhong University of Science and Technology
Wuhan
Hubei
More Union Hospital, Tongji Medical College, Huazhong University of Science and Technology trials in China
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time on our Cookie Policy page. See also our Privacy Policy.